Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis
To evaluate imaging features of microvascular invasion (MVI) in hepatocellular carcinoma (HCC) developed after direct-acting antiviral (DAA) therapy in HCV-related cirrhosis.
Retrospective cohort study on 344 consecutive patients with HCV-related cirrhosis treated with DAA and followed for 48–74 weeks. Using established imaging criteria for MVI, HCC features were analysed and compared with those in nodules not occurring after DAA.
After DAA, HCC developed in 29 patients (single nodule, 18 and multinodular, 11). Median interval between therapy end and HCC diagnosis was 82 days (0–318). Forty-one HCC nodules were detected (14 de novo, 27 recurrent): maximum diameter was 10–20 mm in 27, 20–50 mm in 13, and > 50 mm in 1. Imaging features of MVI were present in 29/41 nodules (70.7%, CI: 54–84), even in 17/29 nodules with 10–20 mm diameter (58.6%, CI: 39–76). MVI was present in only 17/51 HCC nodules that occurred before DAA treatment (33.3%, CI: 22–47) (p= 0.0007). MVI did not correlate with history of previous HCC.
HCC occurs rapidly after DAA therapy, and aggressive features of MVI characterise most neoplastic nodules. Close imaging evaluations are needed after DAA in cirrhotic patients.
• In HCV cirrhosis, hepatocellular carcinoma develops soon after direct-acting antiviral therapy.
• HCC presents imaging features of microvascular invasion, predictive of more aggressive progression.
• Cirrhotic patients need aggressive and close monitoring after direct-acting antiviral therapy.
KeywordsHepatitis C Liver neoplasms Computed tomography Magnetic resonance imaging Drug side effects
Barcelona clinic liver cancer
Hepatitis B virus
Hepatitis C virus
Magnetic resonance imaging
Non-smooth tumour margins
Percutaneous ethanol injection
Sustained virological response
Two-trait predictor of venous invasion
The authors state that this work has not received any funding.
Compliance with ethical standards
The scientific guarantor of this publication is Stefano Brillanti, M.D., Department of Medical and Surgical Sciences, University of Bologna, Italy.
Conflict of interest
The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Institutional Review Board approval was obtained.
Written informed consent was obtained from all subjects (patients) in this study.
• case-control study
• performed at one institution
- 1.AASLD-IDSA (2017) Recommendations for testing, managing, and treating hepatitis C. Available via http://www.hcvguidelines.org. Accessed on 31 Jul 2017
- 16.Lee S, Kim SH, Lee JE, Sinn DH, Park CK (2017) Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol. https://doi.org/10.1016/j.jhep.2017.04.024
- 18.Romano A, Capra F, Piovesan S et al (2016) Incidence and pattern of "de novo" hepatocellular carcinoma in HCV patients treated with oral DAAs. Hepatology 63:10AGoogle Scholar
- 19.Reig M, Mariño Z, Perelló C et al (2017) Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth. J Hepatol 66:PS-031Google Scholar